These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36551743)

  • 21. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
    Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
    Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.
    Karres D; Ali S; van Hennik PB; Straus S; Josephson F; Thole G; Glerum PJ; Herberts C; Babae N; Herold R; Papadouli I; Pignatti F
    Oncologist; 2020 Jun; 25(6):e976-e981. PubMed ID: 32154610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield.
    Villa CH; Shore T; Van Besien K; Cushing M
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1867-75. PubMed ID: 22796644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Third time's a charm? Mobilization of autologous peripheral blood stem cells in patients with two previous failed mobilizations with plerixafor.
    Zhuang L; Boriboonnangkul P; Wang S; Yuan S
    Transfusion; 2020 Jun; 60(6):1253-1259. PubMed ID: 32483875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
    Holmberg LA; Linenberger M; Connelly-Smith L
    Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Automated collection of peripheral blood stem cells with the COBE spectra for autotransplantation.
    Heuft HG; Dubiel M; Kingreen D; Oertel J; De Reys S; Rick O; Serke S; Schwella N
    Vox Sang; 2000; 79(2):94-9. PubMed ID: 11054047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Plerixafor Use at Different Peripheral Blood CD34
    Shah EE; Young RP; Wong SW; Damon LE; Wolf JL; Shah ND; Leavitt AD; Loeffler P; Martin TG
    Biol Blood Marrow Transplant; 2020 May; 26(5):876-883. PubMed ID: 31785375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of good and poor mobilizers on hematopoietic progenitor cell collection efficiency and product quality.
    Azzouqa AM; Jouni K; Roy V; Zubair AC
    J Clin Apher; 2019 Feb; 34(1):39-43. PubMed ID: 30426567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective randomized and crossover comparison of two apheresis machines for peripheral blood stem cell collection: a multicenter study.
    Ikeda K; Minakawa K; Muroi K; Fujiwara SI; Yamada-Fujiwara M; Fujimori Y; Tanosaki R; Ohto H;
    Transfusion; 2016 Nov; 56(11):2839-2847. PubMed ID: 27572290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
    Yuan S; Nademanee A; Kaniewski M; Palmer J; Shayani S; Wang S
    Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
    Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F
    Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of two apheresis systems for autologous stem cell collections in pediatric oncology patients.
    Even-Or E; Eden-Walker A; Di Mola M; McDougall E; Schechter T; Ali M; Svajger G; Gassas A; Licht C; Krueger J
    Transfusion; 2017 Jan; 57(1):122-130. PubMed ID: 27696435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison between intermittent and continuous leukapheresis protocols for autologous hematopoietic stem cell collections in children.
    Ali S; Chiang KY; Even-Or E; Di Mola M; Schechter T; Ali M; McDougall E; Svajger G; Licht C; Krueger J
    J Clin Apher; 2019 Dec; 34(6):646-655. PubMed ID: 31424127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
    Yang C; Dehghani M; Hopman W; Bhella S
    J Clin Apher; 2022 Aug; 37(4):348-353. PubMed ID: 35218068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Two Apheresis Systems of COBE and Optia for Autologous Peripheral Blood Stem Cell Collection.
    Lee SN; Sohn JY; Kong JH; Eom HS; Lee H; Kong SY
    Ann Lab Med; 2017 Jul; 37(4):327-330. PubMed ID: 28445013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach.
    Alsaeed AS; Najib MJ; Al Amoudi SM; Elhemaidi IY; Absi AA; Al Ahmadi MD; Eldadah SK; Rajkhan WA; Khalil MM; Almohammadi MH
    Saudi Med J; 2022 Jun; 43(6):626-632. PubMed ID: 35675941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Amicus and COBE Spectra for allogenic peripheral blood stem cell harvest: Study from tertiary care centre in India.
    Setia RD; Arora S; Handoo A; Dadu T; Choudhary D; Sharma SK; Kharya G; Khandelwal V; Sachdeva P; Doval D; Bakliwal A; Kapoor M; Bajaj S; Bachchas V; Singh P
    Transfus Apher Sci; 2017 Jun; 56(3):439-444. PubMed ID: 28528807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients.
    Teusink A; Pinkard S; Davies S; Mueller M; Jodele S
    Transfusion; 2016 Jun; 56(6):1402-5. PubMed ID: 27079854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.